G6PD Deficiency (Acute Hemolysis)

1. Comprehensive Introduction & Overview

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency represents the most prevalent human enzymopathy, affecting an estimated 400 to 500 million individuals globally. It is an X-linked recessive hereditary condition characterized by a functional deficit in the G6PD enzyme, which is critical for the maintenance of the erythrocyte’s antioxidant defense system.

When G6PD-deficient individuals are exposed to specific oxidative stressors—ranging from pharmacological agents and infections to the ingestion of fava beans (favism)—the red blood cells (RBCs) lose their ability to neutralize reactive oxygen species (ROS). This leads to acute hemolytic anemia, a clinical crisis that can range from mild jaundice to life-threatening hemoglobinuria and acute kidney injury. This guide serves as an authoritative resource for clinicians, researchers, and medical professionals managing the complexities of acute hemolysis in the context of G6PD deficiency.

2. Deep-Dive: Technical Specifications and Mechanisms

The Biochemical Pathway

The G6PD enzyme is the rate-limiting step in the Pentose Phosphate Pathway (PPP). In mature erythrocytes, which lack mitochondria, the PPP is the exclusive source of Nicotinamide Adenine Dinucleotide Phosphate (NADPH).

• NADPH Function: NADPH is required by glutathione reductase to maintain a pool of reduced glutathione (GSH).
• GSH Function: Reduced glutathione is the essential substrate for glutathione peroxidase, the enzyme responsible for neutralizing hydrogen peroxide and other free radicals into water.

Pathophysiological Cascade

1. Oxidative Stress: Exposure to oxidant drugs or metabolites (e.g., primaquine, sulfonamides) triggers the production of ROS.
2. Depletion of NADPH: Without sufficient G6PD activity, NADPH levels fall, and the cell cannot regenerate reduced glutathione.
3. Hemoglobin Oxidation: Unneutralized ROS oxidize hemoglobin sulfhydryl groups, leading to the formation of denatured hemoglobin precipitates known as Heinz bodies.
4. Membrane Damage: Heinz bodies damage the RBC membrane, leading to "bite cell" formation as splenic macrophages attempt to remove these inclusions.
5. Hemolysis: The resulting rigid, damaged RBCs are prematurely destroyed by the reticuloendothelial system (extravascular hemolysis) or undergo lysis directly within the vasculature (intravascular hemolysis).

3. Clinical Indications and Presentation

Clinical Staging/Grading

G6PD deficiency is classified by the World Health Organization (WHO) based on residual enzyme activity and clinical severity:

Standard Presentation

Acute hemolysis typically occurs 24 to 72 hours after exposure to an oxidative trigger. Key clinical indicators include:
* Jaundice: Icteric sclera and yellowing of the skin due to hyperbilirubinemia.
* Dark Urine: "Cola-colored" urine due to hemoglobinuria.
* Pallor: Secondary to acute anemia.
* Abdominal/Back Pain: Frequently reported during severe hemolytic events.
* Tachycardia/Dyspnea: Signs of compensatory mechanisms for decreased oxygen-carrying capacity.

4. Differential Diagnosis

Distinguishing G6PD deficiency from other hemolytic processes is critical. Clinicians should consider:

• Autoimmune Hemolytic Anemia (AIHA): Differentiated by a positive Direct Antiglobulin Test (Coombs test).
• Hereditary Spherocytosis: Characterized by spherocytes on blood smear and positive osmotic fragility tests.
• Pyruvate Kinase Deficiency: Another common enzymopathy; usually presents with chronic rather than episodic hemolysis.
• Microangiopathic Hemolytic Anemias (TTP/HUS): Look for schistocytes and thrombocytopenia.
• Sickle Cell Disease: Identified via hemoglobin electrophoresis.

5. Diagnostic Testing Protocols

First-Line Investigations

1. Complete Blood Count (CBC): Reveals acute drop in hemoglobin and hematocrit; elevated Reticulocyte count (after 3–5 days).
2. Peripheral Blood Smear: Look for "bite cells" (degmacytes) and "blister cells."
3. Biochemical Markers: Elevated LDH, elevated indirect bilirubin, decreased haptoglobin, and hemoglobinuria (on urinalysis).

Confirmatory Testing

• G6PD Quantitative Assay: The gold standard. Note: Testing during an acute crisis may yield "false normal" results because the most deficient cells have already been lysed, leaving a population of younger cells (reticulocytes) that contain higher levels of G6PD.
• Fluorescent Spot Test: A rapid screening tool for qualitative assessment.

6. Risks, Contraindications, and Management

Avoidance of Oxidative Stressors (The "Red List")

Patients must be educated to avoid specific triggers:
* Drugs: Primaquine, rasburicase, dapsone, methylene blue, sulfonamides, and nitrofurantoin.
* Foods: Fava beans (Vicia faba).
* Chemicals: Naphthalene (mothballs).

Management of Acute Hemolysis

1. Remove the Trigger: Identify and discontinue the offending agent immediately.
2. Supportive Care: Hydration is paramount to protect renal function from hemoglobin-induced tubular necrosis.
3. Blood Transfusion: Reserved for patients with symptomatic severe anemia (Hb < 7 g/dL) or signs of hemodynamic instability.
4. Monitor Renal Function: Serial monitoring of BUN/Creatinine is essential.

7. Long-Term Prognosis

The prognosis for G6PD deficiency is excellent, provided the patient is educated regarding trigger avoidance. Unlike many genetic disorders, this condition does not typically shorten life expectancy. However, patients with Class I variants require ongoing hematologic surveillance.

8. Massive FAQ Section

Q1: Is G6PD deficiency contagious?
No. It is a hereditary genetic condition passed down through the X chromosome.

Q2: Why do symptoms only appear after taking certain drugs?
The enzyme deficiency is latent until the RBC is challenged by oxidative stress. Without the stressor, most patients remain asymptomatic.

Q3: Can I eat fava beans if I have G6PD deficiency?
No. Fava beans contain vicine and convicine, which are potent oxidants. Ingestion can trigger severe hemolysis (favism).

Q4: Should I be tested for G6PD before starting anti-malarial medication?
Yes. Primaquine, a standard anti-malarial, is a major trigger for hemolysis in G6PD-deficient patients.

Q5: Why did my G6PD test come back normal during an acute attack?
The test may be falsely normal because the older, enzyme-deficient cells have been destroyed, leaving younger, enzyme-rich reticulocytes in the circulation. Repeat the test 3–4 weeks after the crisis.

Q6: Are there different types of G6PD deficiency?
Yes. The WHO classifies them into five classes based on the severity of enzyme deficiency and clinical impact.

Q7: Can G6PD deficiency cause chronic anemia?
Yes, in Class I variants, where the enzyme is severely dysfunctional, patients may experience chronic non-spherocytic hemolytic anemia.

Q8: Are women affected by G6PD deficiency?
Yes. Because it is X-linked, women can be carriers or affected if they are homozygous for the mutation or due to skewed X-inactivation (lyonization).

Q9: What is the risk of kidney failure?
The risk is secondary to hemoglobinuria. Rapid breakdown of RBCs releases free hemoglobin into the blood, which can precipitate in the renal tubules, causing acute tubular necrosis.

Q10: Is there a cure for G6PD deficiency?
Currently, there is no gene therapy-based cure. Management relies entirely on avoidance of triggers and supportive care during crisis events.

9. Conclusion

G6PD deficiency is a classic example of pharmacogenetics. By understanding the underlying biochemical vulnerability—the failure of the Pentose Phosphate Pathway to generate NADPH—clinicians can effectively prevent life-threatening hemolytic events. Vigilance regarding drug prescriptions, patient education on dietary triggers, and timely recognition of hemolytic markers remain the pillars of successful clinical management. Practitioners should maintain a high index of suspicion in patients presenting with unexplained jaundice or dark urine, particularly in populations of Mediterranean, African, or Southeast Asian descent.